ImmuCell (ICCC) reported preliminary Q4 sales late Thursday of $7.8 million, up from $5.1 million a year earlier.
The full-year total sales stand at $26.5 million, up from $17.5 million in 2023, according to the company.
Analyst estimates were not available for comparison.
ImmuCell said its annualized production for the quarter ended Dec. 31 was about 103% of estimated full capacity and helped reduce its orders backlog to $4.4 million as of Jan. 1, from $9.4 million as of Jan. 1, 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.